DynamX

DynamX is a novel sirolimus-eluting coronary bioadaptor system developed for the treatment of symptomatic ischemic heart disease due to discrete de novo native coronary artery lesions. Unlike conventional drug-eluting stents (DES), which are rigid and can restrict natural vessel movement, the DynamX bioadaptor features a unique hybrid design with metallic helical strands connected by resorbable polymer links. After implantation, the device undergoes three phases: - The initial locked phase establishes maximum flow lumen and restores blood flow. - As the absorbable polymer coating is resorbed (within months), the helical strands unlock and separate, allowing adaptive vessel growth while maintaining luminal support. - In its final phase, separated helical strands provide dynamic support that restores vessel pulsatility and compliance—enabling physiological adaptation to blood flow demands. The system elutes sirolimus (not novolimus as previously used in earlier versions) from a bioresorbable polymer for approximately 3 months post-implantation. This mechanism aims to reduce plaque progression, restore normal vessel function including hemodynamic modulation and pulsatility, and potentially lower adverse event rates compared to standard DES[1][4][5][6][7]. DynamX has demonstrated noninferiority or superiority over contemporary DES in randomized controlled trials regarding target lesion failure rates and cardiovascular outcomes at up to three years follow-up[3][5][7]. It has received FDA Breakthrough Device Designation but is not yet approved for sale in the United States as of June 2025[4][6].

Brand names

DynamX

Other names

DynamX BioadaptorDynamX Sirolimus-Eluting Coronary Bioadaptor SystemDynamX Coronary Bioadaptor System